OssDsign Exceeds 200 Patients in Prospective Spinal Fusion Registry

OssDsign Catalyst Bone Substitute

OssDsign has enrolled 200 patients in the PROPEL multi-center prospective spinal fusion registry. PROPEL was initiated in March 2022 to gather real-world data from patients who have been treated with OssDsign Catalyst.

OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us